血清Caspase-1是创伤性脑损伤患者独立预后因素
入院时Caspase-1在TBI患者高于对照(157.9 vs 108.5 pg/mL,p<0.05),不良结局者高于良好结局者(189.5 vs 144.1 pg/mL,p=0.009),死亡者高于存活者(213.6 vs 146.8 pg/mL,p=0.03)。校正临床和影像学预后因素后,入院Caspase-1是6个月不良结局的独立预测因子(OR 1.05,95%CI 1-1.11,p=0.05)。Caspase-1与所研究影像学变量无相关性。
要点
- 入院时血清Caspase-1在TBI患者高于健康对照(157.9 vs 108.5 pg/mL,p<0.05),24小时时无差异。
- 入院Caspase-1在6个月不良结局(GOSE 1-4)者高于良好结局者(189.5 vs 144.1 pg/mL,p=0.009)。
- 入院Caspase-1在死亡患者高于存活者(213.6 vs 146.8 pg/mL,p=0.03)。
- 校正已知临床和影像学预后指标后,入院Caspase-1是6个月不良结局独立预测因子(OR 1.05,95%CI 1-1.11,p=0.05)。
- Caspase-1水平随GCS严重程度升高:重度TBI高于中度、轻度及健康对照(p<0.001)。
适用人群与场景
- 需住院的TBI患者,来自单中心大学医院,前瞻性观察性研究。
- 排除人群原文未提及。
诊断标准与关键阈值
- 结局定义:死亡为GOSE评分1分;不良结局为GOSE评分1-4分。
- TBI严重程度按GCS分为轻度、中度、重度(原文未给出具体GCS界值)。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 入院时Caspase-1在TBI患者高于对照(157.9 vs 108.5 pg/mL,p<0.05),24小时无差异。
- 入院Caspase-1在不良结局者高于良好结局者(189.5 vs 144.1 pg/mL,p=0.009),死亡者高于存活者(213.6 vs 146.8 pg/mL,p=0.03)。
- 多因素logistic回归:入院Caspase-1是6个月不良结局独立预测因子(OR 1.05,95%CI 1-1.11,p=0.05)。
- Caspase-1与所研究影像学变量无相关性;重度TBI者Caspase-1高于中度、轻度及健康对照(p<0.001)。
证据类型、等级与局限
- 证据类型:前瞻性观察性队列研究。
对床旁实践的改变
- 入院时Caspase-1可作为TBI预后评估的候选生物标志物,与GCS严重程度相关,但与影像学变量无关。
- 原研究为观察性单中心研究,尚不能据此将Caspase-1作为常规决策阈值或改变现有TBI处置流程。
- 适用人群为需住院的TBI患者;原文未提及排除人群及儿科等特殊人群的适用性。
指南或共识出处
- 原文未提及指南或共识出处;文献来源为Neurocrit Care。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The objectives of this study were to assess the association between serum caspase 1 levels and known clinical and radiological prognostic factors and determine whether caspase 1was a more powerful predictor of outcome after traumatic brain injury (TBI) than clinical indices alone, to determine the association between the serum levels of caspase 1 and the 6-month outcome, and to evaluate if there is any association between caspase 1 with clinical and radiological variables.
METHODS: This prospective and observational study was conducted in a university hospital and included patients with TBI who required hospital admission. Serum samples were collected at hospital admission and 24 h after TBI. Caspase 1 levels were determined by enzyme-linked immunosorbent assay. Receiver operating characteristic curves were obtained to test the potential of caspase 1 to predict mortality (Glasgow Outcome Scale Extended score of 1) and unfavorable outcome (Glasgow Outcome Scale Extended scores of 1-4). Multivariate logistic regression was used to assess the effect of serum caspase 1 levels, adjusted by known clinical and radiological prognostic indices, on the outcome.
RESULTS: One hundred thirty-two patients and 33 healthy controls were included. We obtained 6-month outcome in 118 patients. On admission, the mean serum levels of caspase 1 were higher in patients with TBI compared with controls (157.9 vs. 108.5 pg/mL; p < 0.05) but not at 24 h after TBI. Serum caspase 1 levels on admission were higher in patients with unfavorable outcomes (189.5 vs. 144.1 pg/mL; p = 0.009). Similarly, serum caspase 1 levels on admission were higher in patients who died vs. patients who survived (213.6 vs. 146.8 pg/mL; p = 0.03). A logistic regression model showed that the serum caspase 1 level on admission was an independent predictor of 6-month unfavorable outcomes (odds ratio 1.05; 95% confidence interval 1-1.11; p = 0.05). Caspase 1 levels were higher in patients with severe TBI compared with those with moderate TBI, those with mild TBI, and healthy controls (p < 0.001). We did not find any correlation between caspase 1 and the radiological variables studied.
CONCLUSIONS: In this cohort of patients with TBI, we show that serum caspase 1 protein levels on admission are an independent prognostic factor after TBI. Serum caspase 1 levels on admission are higher in patients who will present unfavorable outcomes 6 months after TBI. Caspase 1 levels on admission are associated with the injury severity determined by the Glasgow Coma Scale.
参考来源
- Pérez-Bárcena J, Rodríguez Pilar J, Salazar O, et al. Serum Caspase-1 as an Independent Prognostic Factor in Traumatic Brain Injured Patients. Neurocrit Care. 2021. PMID: 34498205. doi:10.1007/s12028-021-01340-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。